×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Clinical_Trial: Clostridium Butyricum for Motor and Non-motor Symptoms in Pa
clinical_trial
661 words
KG: Clostridium Butyricum for Motor and Non-motor Symptoms in Parkinson's Disease
2026-03-31
clinical-trial
parkinson
microbiome
probiotic
gut-brain-axis
butyricum
Contents
Clostridium Butyricum for Motor and Non-motor Symptoms in Parkinson's Disease
Knowledge Graph
Related Hypotheses (21)
Purinergic Signaling Polarization Control
Score: 0.55
Mechanosensitive Ion Channel Reprogramming
Score: 0.51
Lipid Droplet Dynamics as Phenotype Switches
Score: 0.46
Hippocampal CA3-CA1 synaptic rescue via DHHC2-mediated PSD95
Score: 0.69
Multiplexed Base Editing for Simultaneous Neuroprotective Ge
Score: 0.53
Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna
Score: 0.68
Digital Twin-Guided Metabolic Reprogramming
Score: 0.61
Smartphone-Detected Motor Variability Correction
Score: 0.56
Chromatin Accessibility Restoration via BRD4 Modulation
Score: 0.56
Epigenetic Memory Erasure via TET2 Activation
Score: 0.52
Gut Barrier Permeability-α-Synuclein Axis Modulation
Score: 0.49
Perforant Path Presynaptic Terminal Protection Strategy
Score: 0.48
Astrocyte-Mediated Neuronal Epigenetic Rescue
Score: 0.48
TET2-Mediated Demethylation Rejuvenation Therapy
Score: 0.47
Arginine Methylation Enhancement Therapy
Score: 0.46
Microbial Metabolite-Mediated α-Synuclein Disaggregation
Score: 0.45
Piezoelectric Nanochannel BBB Disruption
Score: 0.41
Temporal TET2-Mediated Hydroxymethylation Cycling
Score: 0.41
Partial Neuronal Reprogramming via Modified Yamanaka Cocktai
Score: 0.40
KDM6A-Mediated H3K27me3 Rejuvenation
Score: 0.38
DNMT1-Targeting Antisense Oligonucleotide Reset
Score: 0.36
Show 16 more
Related Analyses (16)
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
Epigenetic reprogramming in aging neurons
neurodegeneration · archived
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · failed
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · archived
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed
Immune atlas neuroinflammation analysis in neurodegeneration
Neuroinflammation · archived
Cell type vulnerability in Alzheimer's Disease (SEA-AD data)
neurodegeneration · failed
Cell type vulnerability in Alzheimer's Disease (SEA-AD data
neurodegeneration · archived
TREM2 Therapeutic Strategy Post-INVOKE-2
neurodegeneration · completed
GBA-Synuclein Loop Therapeutics for PD
neurodegeneration · completed
Gut-Brain Axis Therapeutics for AD
neurodegeneration · completed
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · completed
Show 11 more
Related Experiments (30)
Animal Model Comparison for Neurodegenerative Disease Therap
clinical · proposed · Score: 0.40
Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
Glymphatic-Circadian Axis Enhancement Therapy for Parkinson'
clinical · proposed · Score: 0.40
Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag
clinical · proposed · Score: 0.40
Neural Oscillation Dysfunction Validation in Parkinson's Dis
clinical · proposed · Score: 0.40
Oligodendrocyte-Myelin Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
Proteasome-Ubiquitin System Dysfunction Validation in Parkin
clinical · proposed · Score: 0.40
Protein Aggregation Kinetic Validation Results
validation · proposed · Score: 0.40
Purinergic Signaling Dysfunction Validation in Parkinson's D
clinical · proposed · Score: 0.40
Regulated Necrosis Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
Stress Granule Dysfunction Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
Experiment Validation: In vitro ThT Assay
validation · proposed · Score: 0.40
AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Thera
validation · proposed · Score: 0.40
AAV-LRRK2 IND-Enabling Study Design
clinical · proposed · Score: 0.40
AAV Serotype Comparison for LRRK2 Knockdown in PD
validation · proposed · Score: 0.40
Alpha-Synuclein SAA Kinetics Study — Biological Staging Back
clinical · proposed · Score: 0.40
Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio
clinical · proposed · Score: 0.40
Computational Modeling of Alpha-Synuclein Propagation in PD
validation · proposed · Score: 0.40
Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation
validation · proposed · Score: 0.40
Alpha-Synuclein Seed Amplification Assay Validation
clinical · proposed · Score: 0.40
Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation
exploratory · proposed · Score: 0.40
Antiviral Therapy Trial for Parkinson's Disease
clinical · proposed · Score: 0.40
Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson'
clinical · proposed · Score: 0.40
Axonal Transport Dysfunction Validation in Parkinson's Disea
clinical · proposed · Score: 0.40
cGAS-STING Pathway Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
Chaperone-Mediated Autophagy Dysfunction in PD - Experiment
clinical · proposed · Score: 0.40
Combination Therapy Sequencing in Parkinson's Disease
validation · proposed · Score: 0.40
CRISPR Gene Correction Approaches for CBS/PSP
clinical · proposed · Score: 0.40
Alpha-Synuclein Staging and Spreading in DLB — Spatial Propa
validation · proposed · Score: 0.40
DNA Damage Repair Deficiency Validation Study in Parkinson's
clinical · proposed · Score: 0.40
Show 25 more
See Also (15)
Yoga Therapy for Neurodegeneration
therapeutic · Pages share 3 hypotheses
YAP/TEAD Pathway Modulators for Neurodegeneration
therapeutic · Pages share 3 hypotheses
Wnt Signaling Modulators for Neurodegeneration
therapeutic · Pages share 3 hypotheses
vitamin-d-therapy-neurodegeneration
therapeutic · Pages share 3 hypotheses
Vitamin B Complex Therapy for Neurodegeneration
therapeutic · Pages share 3 hypotheses
VIP/VPAC Receptor Modulators for Neurodegeneration
therapeutic · Pages share 3 hypotheses
Vestibular and Balance Therapy for CBS/PSP
therapeutic · Pages share 3 hypotheses
VEGF and Angiogenesis Therapy
therapeutic · Pages share 3 hypotheses
Urolithin A for Neurodegeneration
therapeutic · Pages share 3 hypotheses
Urolithin A for Neurodegeneration
therapeutic · Pages share 3 hypotheses
tudca-udca-neurodegeneration
therapeutic · Pages share 3 hypotheses
TRPM8 Agonists for Neurodegeneration
therapeutic · Pages share 3 hypotheses
Triple Incretin Agonists (GLP-1/GIP/Glucagon) for Neuro
therapeutic · Pages share 3 hypotheses
TREM2 Agonist Therapy for Neurodegeneration
therapeutic · Pages share 3 hypotheses
Transcutaneous Vagal Nerve Stimulation (tVNS) for Parki
therapeutic · Pages share 3 hypotheses
Show 10 more
Knowledge Graph (2 edges)
Clostridium Butyricum for Motor and Non-motor Symptoms in Parkinson's Disease
references
BDNF
Clostridium Butyricum for Motor and Non-motor Symptoms in Parkinson's Disease
references
HDAC